Stay updated with breaking news from Human First Discovery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
25.08.2022 - SOMERVILLE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) - Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel ... Seite 1
Analysts’ downgrades for Wednesday, June 1st: Build-A-Bear Workshop (NYSE:BBW) was downgraded by analysts at StockNews.com from a buy rating to a hold rating. Bunge (NYSE:BG) was downgraded by analysts at StockNews.com from a buy rating to a hold rating. Brookdale Senior Living (NYSE:BKD) was downgraded by analysts at StockNews.com from a hold rating to a […]
Research Analysts’ downgrades for Tuesday, May 24th: Antero Resources (NYSE:AR) was downgraded by analysts at Zacks Investment Research from a strong-buy rating to a hold rating. The firm currently has $42.00 price target on the stock. According to Zacks, “Antero Resources has positioned itself among the fast-growing natural gas producers in the United States. The […]
SOMERVILLE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...
SOMERVILLE, Mass., March 01, 2022 -- Finch Therapeutics Group, Inc. , a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class... | March 2, 2022